Lundbeck acquires Aarhus-based biotech company NeuronIcon and its technologies. At the same time, Lundbeck has signed a collaborative agreement with the University of Arhus on additional neurology research.
The company reported that the acquisition of NeuronIcon provides them with opportunities to develop new therapies for acute brain damage after strokes or skull fractures, areas in which there is presently a great need for effective treatment options.
Lundbeck has signed an agreement with the University of Aarhus on supporting the university’s continuing research in the area to which NeuronIcon dedicates its resources. The agreement gives Lundbeck certain rights to any new discoveries made by the university scientists over the course of the next three years.
Anders Nykjaer, CEO and co-founder of NeuronIcon, said: “We have been very happy with our collaboration with Lundbeck these past few years. Lundbeck has the expertise to ensure the successful commercial utilisation of NeuronIcon’s discoveries in a number of disabling psychiatric and neuro-degenerative disorders.”